Background

Large B-cell lymphoma often remains difficult to achieve complete remission with conventional chemotherapy and immunotherapy (e.g., CD20 antibodies) alone. Recently, CAR T-cell therapy has demonstrated substantial efficacy in high‑risk patient populations, challenging the standard of care. However, strategies to effectively eradicate minimal residual disease that persists before or after CAR T treatment are lacking.

Study Design

This is a Phase 2 trial that opened on September 24, 2024, currently enrolling patients, and is sponsored by Abramson Cancer Center of Penn Medicine. Epocritamab (epcoritamab) will be administered before and after CAR T-cell therapy to assess feasibility and efficacy. The specific primary endpoint and anticipated completion date have not yet been disclosed.

Differentiation and Mechanism

Epocritamab is a bispecific antibody that simultaneously targets CD3 and CD20, directly activating the patient’s T cells to attack tumor cells. Unlike CAR T cells, its manufacturing process is less complex, allowing rapid deployment, and it can provide an additional immune attack on residual disease after CAR T infusion. This mechanistic distinction suggests the potential to complement the limitations of existing CAR T therapies.

Market and Clinical Implications

If the combined use of epcoritamab and CAR T cells proves successful, it could introduce a novel combination strategy into the treatment paradigm for large B-cell lymphoma. This may act as a catalyst for biopharma companies to expand pipelines that integrate bispecific antibodies with cellular therapies. Moreover, increased therapeutic options in the clinic could enable more personalized treatment approaches.

Risks and Outlook

The study remains early‑stage, and the sequential administration of two immunotherapies raises concerns about toxicity and immune‑related adverse events. Limited patient enrollment could impede data collection. Considering these variables, careful observation is warranted until data become available, likely within the next two to three years.